BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 29604904)

  • 1. Epithelial-to-Mesenchymal Transition: Liaison between Cancer Metastasis and Drug Resistance.
    Du F; Liu H; Lu Y; Zhao X; Fan D
    Crit Rev Oncog; 2017; 22(3-4):275-282. PubMed ID: 29604904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Roles of epithelial-mesenchymal transition in cancer drug resistance.
    Shang Y; Cai X; Fan D
    Curr Cancer Drug Targets; 2013 Nov; 13(9):915-29. PubMed ID: 24168191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting Epithelial-Mesenchymal Transition (EMT) to Overcome Drug Resistance in Cancer.
    Du B; Shim JS
    Molecules; 2016 Jul; 21(7):. PubMed ID: 27455225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EMT, CTCs and CSCs in tumor relapse and drug-resistance.
    Mitra A; Mishra L; Li S
    Oncotarget; 2015 May; 6(13):10697-711. PubMed ID: 25986923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epithelial-mesenchymal transition and drug resistance: role, molecular mechanisms, and therapeutic strategies.
    Sui H; Zhu L; Deng W; Li Q
    Oncol Res Treat; 2014; 37(10):584-9. PubMed ID: 25342509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epithelial-mesenchymal plasticity of breast cancer stem cells: implications for metastasis and therapeutic resistance.
    Luo M; Brooks M; Wicha MS
    Curr Pharm Des; 2015; 21(10):1301-10. PubMed ID: 25506895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epithelial Mesenchymal Transition in Aggressive Lung Cancers.
    Mittal V
    Adv Exp Med Biol; 2016; 890():37-56. PubMed ID: 26703798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting microRNAs in epithelial-to-mesenchymal transition-induced cancer stem cells: therapeutic approaches in cancer.
    Garg M
    Expert Opin Ther Targets; 2015 Feb; 19(2):285-97. PubMed ID: 25563894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epithelial-mesenchymal transition in colorectal cancer metastasis: A system review.
    Cao H; Xu E; Liu H; Wan L; Lai M
    Pathol Res Pract; 2015 Aug; 211(8):557-69. PubMed ID: 26092594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PHD3 Controls Lung Cancer Metastasis and Resistance to EGFR Inhibitors through TGFα.
    Dopeso H; Jiao HK; Cuesta AM; Henze AT; Jurida L; Kracht M; Acker-Palmer A; Garvalov BK; Acker T
    Cancer Res; 2018 Apr; 78(7):1805-1819. PubMed ID: 29339541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting EMT in cancer: opportunities for pharmacological intervention.
    Davis FM; Stewart TA; Thompson EW; Monteith GR
    Trends Pharmacol Sci; 2014 Sep; 35(9):479-88. PubMed ID: 25042456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting signal transduction pathways of cancer stem cells for therapeutic opportunities of metastasis.
    Iqbal W; Alkarim S; AlHejin A; Mukhtar H; Saini KS
    Oncotarget; 2016 Nov; 7(46):76337-76353. PubMed ID: 27486983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The epithelial-mesenchymal transition and cancer stem cells: functional and mechanistic links.
    Liu X; Fan D
    Curr Pharm Des; 2015; 21(10):1279-91. PubMed ID: 25506898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The emerging molecular machinery and therapeutic targets of metastasis.
    Sun Y; Ma L
    Trends Pharmacol Sci; 2015 Jun; 36(6):349-59. PubMed ID: 25939811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The epithelial to mesenchymal transition (EMT) and cancer stem cells: implication for treatment resistance in pancreatic cancer.
    Zhou P; Li B; Liu F; Zhang M; Wang Q; Liu Y; Yao Y; Li D
    Mol Cancer; 2017 Feb; 16(1):52. PubMed ID: 28245823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NANOGP8 is the key regulator of stemness, EMT, Wnt pathway, chemoresistance, and other malignant phenotypes in gastric cancer cells.
    Ma X; Wang B; Wang X; Luo Y; Fan W
    PLoS One; 2018; 13(4):e0192436. PubMed ID: 29689047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contributions of epithelial-mesenchymal transition and cancer stem cells to the development of castration resistance of prostate cancer.
    Li P; Yang R; Gao WQ
    Mol Cancer; 2014 Mar; 13():55. PubMed ID: 24618337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of epithelial-mesenchymal transition-regulating transcription factors in anti-cancer drug resistance.
    Seo J; Ha J; Kang E; Cho S
    Arch Pharm Res; 2021 Mar; 44(3):281-292. PubMed ID: 33768509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The therapeutic potential of targeting the epithelial-mesenchymal transition in cancer.
    Ginnebaugh KR; Ahmad A; Sarkar FH
    Expert Opin Ther Targets; 2014 Jul; 18(7):731-45. PubMed ID: 24758643
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pancreatic cancer stem cells: emerging target for designing novel therapy.
    Li Y; Kong D; Ahmad A; Bao B; Sarkar FH
    Cancer Lett; 2013 Sep; 338(1):94-100. PubMed ID: 22445908
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.